Renascience's Skin-Cancer Drug RS5614 Gets Japan's Orphan Status, Not Yet Approval
Japan's health ministry designated Renascience's RS5614 an orphan drug for the rare skin cancer cutaneous angiosarcoma, extending exclusivity and adding a pricing premium, while the company discusses a Phase 3 trial with Japan's PMDA aimed at regulatory approval.